Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Trastuzumab MeSH Descriptor Data 2026


MeSH Heading
Trastuzumab
Tree Number(s)
D12.776.124.486.485.114.224.060.875
D12.776.124.790.651.114.224.060.875
D12.776.377.715.548.114.224.200.875
Unique ID
D000068878
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000068878
Scope Note
A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.
Entry Term(s)
Herceptin
Trastuzumab beta
Trastuzumab-qyyp
Trazimera
Pharm Action
Antineoplastic Agents, Immunological
Registry Numbers
P188ANX8CK
0
Related Numbers
180288-69-1
See Also
Erb-b2 Receptor Tyrosine Kinases
Public MeSH Note
2016; TRASTUZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 1998-2015
History Note
2016 (1998)
Date Introduced
2016/01/01
Last Updated
2026/01/01
Trastuzumab Preferred
Herceptin Narrower
Trazimera Narrower
page delivered in 0.138s